Triple
T1169606
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ionis Pharmaceuticals |
E24882
|
entity |
| Predicate | coDevelopedWith |
P6901
|
FINISHED |
| Object | Biogen |
E3807
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen | Statement: [Ionis Pharmaceuticals, coDevelopedWith, Biogen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biogen Context triple: [Ionis Pharmaceuticals, coDevelopedWith, Biogen]
-
A.
Biogen
chosen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
E.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: coDevelopedWith Context triple: [Ionis Pharmaceuticals, coDevelopedWith, Biogen]
-
A.
developedWith
Indicates that something was created, built, or produced using a specified tool, technology, method, or collaborator.
-
B.
coDeveloperOf
chosen
Indicates that two or more entities jointly developed or collaborated in creating the same project, product, or work.
-
C.
developedAs
Indicates that one entity was created, designed, or evolved specifically to function as or replace another entity.
-
D.
developedUnder
Indicates that something was created, produced, or brought into existence while being subject to the authority, guidance, or conditions imposed by a particular person, organization, regime, or framework.
-
E.
developedInParallelWith
Indicates that two or more things were created or progressed during the same time period, with their development processes occurring concurrently rather than sequentially.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac93b6343c8190af6e28ccdaab6562 |
completed | March 7, 2026, 9:08 p.m. |
| PD | Predicate disambiguation | batch_69a4bb5656948190b0b1d5446ad06005 |
completed | March 1, 2026, 10:19 p.m. |
Created at: March 1, 2026, 7:45 p.m.